Transaction DateRecipientSharesTypePriceValue
10th September 2020Henry A Mckinnell5.853Grant/award etc.$286.39$1,676.24
10th September 2020Henry A Mckinnell99Grant/award etc.$286.88$28,401.12
3rd August 2020(International) Ltd Vifor31,823Open or private sale$53.62$1,706,307.89
3rd August 2020(International) Ltd Vifor16,650Open or private sale$54.58$908,806.95
3rd August 2020(International) Ltd Vifor785Open or private sale$52.92$41,540.24
31st July 2020(International) Ltd Vifor10,009Open or private sale$51.74$517,867.66
31st July 2020(International) Ltd Vifor29,699Open or private sale$52.57$1,561,252.67
31st July 2020(International) Ltd Vifor694Open or private sale$54.33$37,704.19
30th July 2020(International) Ltd Vifor1,156Open or private sale$53.37$61,692.48
30th July 2020(International) Ltd Vifor24,458Open or private sale$54.43$1,331,354.11
Chemo Centryx
Chemo Centryx logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.


ChemoCentryx, Inc. focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.


Ticker: CCXI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1340652
Employees: 82
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $333 M (0%)
Assets, Current: $507 M (190%)
Property, Plant and Equipment, Net: $6 M (158%)
Other Assets, Noncurrent: $1 M (-18%)
Assets: $542 M (159%)
Accounts Payable, Current: $3 M (122%)
Accrued Liabilities, Current: $19 M (0%)
Liabilities, Current: $56 M (-4%)
Long-term Debt, Excluding Current Maturities: $24 M (0%)
Other Liabilities, Noncurrent: $746 Th (34%)
Liabilities: $121 M (-15%)
Common Stock, Value, Issued: $69 Th (15%)
Common Stock, Shares, Issued: $69 M (14%)
Additional Paid in Capital, Common Stock: $852 M (71%)
Retained Earnings (Accumulated Deficit): $431 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $488 Th (53%)
Stockholders' Equity (Parent): $421 M (0%)
Liabilities and Equity: $542 M (159%)
Revenue: $49 M (-10%)
Research and Development: $19 M (-50%)
General and Administrative Expenses: $10 M (-46%)
Operating Income/Loss: $20 M (1073%)
Other Income, net: $119 Th (-62%)
EPS (basic): $0.32 (0%)
EPS (diluted): $0.29 (0%)